LabCorp
LH
$266.34
+0.44%
Labcorp Holdings Inc. is a leading provider of medical diagnostics and research services, operating as one of the nation's two largest independent clinical laboratories with a broad portfolio of approximately 5,000 clinical lab tests. The company is a dominant market player with roughly 20% share of the independent lab market, distinguished by its extensive network of patient-service centers and capabilities in complex oncology and genomic testing. The current investor narrative is focused on the company's strategic investments in AI and robotics to improve operational efficiency and drive growth, as evidenced by recent positive earnings reports and raised guidance, positioning it as a mature healthcare player leveraging technology for margin expansion and steady growth.…
LH
LabCorp
$266.34
Related headlines
Investment Opinion: Should I buy LH Today?
Rating & Thesis: Hold. Labcorp presents a conflicted profile where solid fundamentals and a reasonable forward valuation are overshadowed by poor technical momentum and earnings volatility, resulting in a 'show me' story that requires proof of sustained execution. The limited analyst coverage (6 analysts) prevents a clear consensus anchor, placing greater emphasis on independent assessment of the AI investment payoff.
Supporting Evidence: The recommendation is grounded in four key data points: 1) The attractive forward P/E of 13.16x suggests embedded earnings growth, 2) Robust annual free cash flow of $1.21B provides a margin of safety, 3) A dominant ~20% market share offers stability, and 4) Strategic AI investments have already contributed to a positive earnings surprise. However, these are counterbalanced by a premium trailing P/E of 23.81x, recent gross margin compression from 29.66% to 26.18%, and severe 1-year underperformance of -27.12%.
Risks & Conditions: The thesis would upgrade to Buy if the stock demonstrates a sustained technical breakout above its 52-week high of $293.72 on the back of consecutive quarters of margin expansion and earnings beats. It would downgrade to Sell if the stock breaks below its 52-week low of $241.81 or if quarterly revenue growth decelerates below 3% YoY. Relative to its own history and sector, the stock is in a gray area—the trailing multiple suggests it is fairly valued to slightly overvalued, but the forward multiple implies it is undervalued if growth expectations are met.
Sign up to view all
LH 12-Month Price Forecast
The outlook for LH is one of cautious optimism tempered by recent performance. The company's strategic pivot to AI and its strong cash flow generation are compelling, but the stock must overcome significant technical damage and prove that margin expansion is sustainable. The base case of range-bound trading is most likely, with the forward valuation providing a floor and the premium trailing multiple capping near-term upside. The stance would upgrade to bullish on confirmation of margin recovery for two consecutive quarters and a technical breakout above $294. It would turn bearish on a breakdown below $242 coupled with declining revenue growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LabCorp's 12-month outlook, with a consensus price target around $346.24 and implied upside of +30.0% versus the current price.
Average Target
$346.24
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$213 - $346
Analyst target range
Analyst coverage for Labcorp is limited, with only 6 analysts providing estimates, which is relatively low for a company of its market cap and suggests it may be under-followed by the broader institutional community. The available data shows consensus estimates for EPS and revenue but does not provide a clear Buy/Hold/Sell distribution, average price target, or target range, making it impossible to calculate implied upside or downside or assess the strength of analyst conviction. The implication of this insufficient analyst coverage is that Labcorp, despite its size, may experience less efficient price discovery and higher volatility due to lower institutional scrutiny, placing greater onus on investors to conduct independent fundamental analysis to gauge its fair value.
Bulls vs Bears: LH Investment Factors
The investment debate for Labcorp centers on a clash between its solid financial foundation and strategic initiatives versus its poor technical performance and earnings volatility. The bull case is supported by strong free cash flow, a reasonable forward valuation, and tangible AI-driven operational improvements. The bear case is underscored by severe market underperformance, recent margin compression, and a premium trailing multiple. Currently, the bearish evidence from price action and sentiment is stronger, as the stock's downtrend persists despite positive fundamentals. The single most important tension is whether the company's strategic investments in AI and efficiency can sustainably reverse the margin compression and re-accelerate earnings growth quickly enough to validate its forward valuation and break the stock's negative momentum.
Bullish
- Strong Free Cash Flow & Financial Health: The company generates robust annual free cash flow of $1.21 billion, providing significant financial flexibility. This supports a healthy current ratio of 1.42 and a moderate debt-to-equity ratio of 0.84, enabling continued investments in growth initiatives and shareholder returns.
- Attractive Forward Valuation: The forward P/E ratio of 13.16x is significantly lower than the trailing P/E of 23.81x, indicating the market expects substantial earnings growth. This forward multiple is reasonable for a stable healthcare leader, especially when compared to a sector average often in the high teens.
- Strategic AI Investments Driving Efficiency: Recent news highlights strategic investments in AI and robotics, which are already improving operations and were cited as a driver for a strong Q1 2026 earnings beat and raised guidance. This positions the company for potential margin expansion and operational efficiency gains.
- Dominant Market Position & Stable Growth: With roughly 20% market share and a network of ~2,000 patient-service centers, Labcorp is a dominant player. Revenue grew 5.6% YoY in Q4 2025, demonstrating stable, albeit modest, growth in its core diagnostics business.
Bearish
- Severe Relative Underperformance & Downtrend: The stock has underperformed the S&P 500 by -27.12% over the past year and is trading near the bottom of its 52-week range (~47% of the range from $241.81 to $293.72). This persistent negative momentum reflects deep-seated investor pessimism that fundamentals have yet to overcome.
- Margin Compression & Earnings Volatility: Q4 2025 gross margin of 26.18% shows compression from 29.66% in Q2 2025. Similarly, Q4 net income of $164.7M and net margin of 4.68% were down significantly from Q3 levels, indicating earnings volatility and potential cost pressures.
- Limited Analyst Coverage & Low Visibility: With only 6 analysts providing estimates, the stock is under-followed for its market cap. This lack of coverage can lead to less efficient price discovery and higher volatility, placing the burden of valuation entirely on investors.
- Premium Trailing Valuation vs. Sector: A trailing P/E of 23.81x trades at a premium to the typical healthcare diagnostics industry average. This premium is vulnerable to compression if the company's growth and margin expansion narrative fails to materialize as expected.
LH Technical Analysis
The stock is in a pronounced downtrend, having declined 2.13% over the past year, which starkly contrasts with the S&P 500's gain of 24.99%, resulting in severe relative underperformance of -27.12%. The current price of $255.82 sits at approximately 47% of its 52-week range ($241.81 to $293.72), indicating it is trading much closer to its annual low, which may signal a value opportunity but also reflects persistent negative momentum and investor pessimism. Recent short-term momentum shows a modest uptick with a 0.84% gain over the past month, yet this is overshadowed by a 2.73% decline over the past three months, suggesting the recent positive move is a weak bounce within a broader bearish context. The stock's beta of 0.877 indicates it is less volatile than the broader market, which has not protected it from significant underperformance, and the high short ratio of 4.75 points to substantial bearish sentiment and potential for a short squeeze on any positive catalyst. Key technical levels are clearly defined, with immediate support at the 52-week low of $241.81 and major resistance at the 52-week high of $293.72; a sustained break below support could trigger a new leg down, while a move above resistance would require a significant shift in fundamentals to reverse the established downtrend.
Beta
0.88
0.88x market volatility
Max Drawdown
-15.2%
Largest decline past year
52-Week Range
$242-$294
Price range past year
Annual Return
+3.0%
Cumulative gain past year
| Period | LH Return | S&P 500 |
|---|---|---|
| 1m | +3.1% | -2.2% |
| 3m | +0.8% | +15.8% |
| 6m | +4.9% | +6.4% |
| 1y | +3.0% | +20.9% |
| ytd | +5.8% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LH Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $3.52 billion representing a 5.6% year-over-year increase; however, examining the sequential quarterly trend from Q1 to Q4 2025 shows revenue peaked in Q3 at $3.56 billion before dipping slightly, indicating stable but not accelerating growth in its core diagnostics business. Profitability is solid with a Q4 net income of $164.7 million and a gross margin of 26.18%, but margins have shown some compression from the higher levels seen in earlier quarters of 2025 (e.g., Q2 gross margin was 29.66%), suggesting potential cost pressures or mix shifts; the net margin of 4.68% in Q4, while positive, is below the full-year net margin indicated in valuation data of 6.28%. The balance sheet and cash flow position is healthy, with a debt-to-equity ratio of 0.84 indicating moderate leverage, a strong current ratio of 1.42 for liquidity, and robust annual free cash flow of $1.21 billion providing ample internal funding for dividends, buybacks, and investments; the return on equity of 10.17% demonstrates adequate, though not exceptional, capital efficiency for the industry.
Quarterly Revenue
$3.5B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.26%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LH Overvalued?
Given the company's consistent profitability with a positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 23.81x, while the forward PE is significantly lower at 13.16x, indicating the market expects substantial earnings growth in the coming year, likely driven by the AI investments and operational improvements highlighted in recent news. Compared to sector averages, Labcorp's trailing PE of 23.81x trades at a premium to the typical healthcare diagnostics & research industry average (which often ranges in the high teens), a premium that may be justified if the company successfully executes on its technology-driven margin expansion and growth initiatives as anticipated. Historically, the stock's own PE ratio has fluctuated significantly, with recent quarterly data showing a range from approximately 20x to over 33x over the past few years; the current trailing multiple near 24x is towards the middle of this historical band, suggesting the stock is neither excessively cheap nor expensive based on its own history, but the lower forward PE implies expectations for multiple compression as earnings are projected to grow.
PE
23.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -29x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Labcorp faces risks from earnings volatility and margin pressure, as evidenced by the Q4 2025 net margin compressing to 4.68% from 7.33% in Q3. While free cash flow is strong at $1.21B, the company carries moderate leverage with a debt-to-equity ratio of 0.84. Revenue, though stable, shows only modest 5.6% YoY growth, indicating dependence on operational efficiency gains rather than top-line acceleration to drive shareholder value, making the stock sensitive to execution missteps on its AI investments.
Market & Competitive Risks: The stock's primary market risk is valuation compression, as its trailing P/E of 23.81x sits at a premium to sector peers. Trading at a 47% position within its 52-week range ($241.81-$293.72) reflects deep negative sentiment that could persist. With a beta of 0.877, the stock is less volatile than the market but has still suffered severe underperformance (-27.12% vs. S&P 500), indicating company-specific and sector-related headwinds are outweighing any defensive characteristics.
Worst-Case Scenario: The worst-case scenario involves a failure of AI/robotics investments to materialize into sustained margin improvement, coupled with a broader healthcare sector slowdown. This could trigger a re-rating to a sector-average P/E in the high teens on stagnant earnings, leading the stock to test and break its 52-week low of $241.81. Given the current price of $255.82, this scenario implies a realistic downside of approximately -5.5% to that technical support level, with further downside possible if earnings estimates are cut, potentially pushing the stock toward a -15% to -20% decline from current levels.
FAQ
The key risks are, in order of severity: 1) Execution Risk: The company's AI/robotics investments may fail to deliver promised margin expansion, as hinted by Q4 2025 gross margin compression to 26.18%. 2) Valuation Risk: The premium trailing P/E of 23.81x is vulnerable to compression if growth stalls. 3) Sentiment & Technical Risk: The stock is in a strong downtrend, underperforming the S&P 500 by 27.12%, and high short interest (ratio 4.75) reflects pervasive bearishness. 4) Low Visibility Risk: Limited coverage from only 6 analysts can lead to higher volatility and inefficient price discovery.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees range-bound trading between $260 and $285 as the company executes its plan steadily. The Bull Case (25% probability) targets $293 to $310, driven by successful AI implementation and a short squeeze. The Bear Case (15% probability) warns of a retest of the 52-week low near $241 if margins deteriorate further. The Base Case is most likely, predicated on the assumption that the company's forward P/E of 13.16x is justified by modest earnings growth and stable cash flow, without a major multiple expansion.
LH sends mixed valuation signals. Its trailing P/E of 23.81x trades at a premium to the healthcare diagnostics sector, suggesting it is overvalued based on current earnings. However, its forward P/E of 13.16x is significantly lower and reasonable, implying the market expects strong earnings growth and that the stock is undervalued on a forward basis. This discrepancy means the valuation is entirely dependent on the company delivering on its projected earnings growth from operational improvements. Currently, it is fairly valued relative to its own historical P/E range.
LH is a conditional buy for patient investors. The forward P/E of 13.16x is attractive for a market leader, and strong free cash flow of $1.21B provides downside support. However, the stock is in a pronounced downtrend, has underperformed the market by 27% over the past year, and needs to prove its AI investments can reverse recent margin compression. It is a good buy for those who believe in the execution of its tech-driven efficiency plan and can tolerate near-term volatility, but not for investors seeking immediate momentum or high growth.
LH is more suitable for a medium to long-term investment horizon (2+ years). Its low beta of 0.877 and modest dividend yield of 1.15% are not attractive for short-term traders seeking volatility or income. The investment thesis revolves around the multi-quarter execution of a technological transformation to improve efficiency—a story that will take time to unfold and be reflected in financials. The significant technical damage also requires time to repair. Therefore, investors should be prepared to hold through volatility to allow the fundamental story to potentially overcome the current negative sentiment.